Founded
Address
Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States
Phone
Website
Recent investment activity
KANDO id: 30972
Company type
Life sciences venture capital firmRelation
Renamed to
Funds managed
| Fund | Type | Vintage | Currency | Committed capital | IRR | x |
|---|---|---|---|---|---|---|
| Clarus IV-A LP | Venture | 2017 | USD | 789,700,000 | ||
| Clarus IV-B LP | Venture | 2017 | USD | 789,700,000 | ||
| Clarus IV-C LP | Venture | 2017 | USD | 789,700,000 | ||
| Clarus IV-D LP | Venture | 2017 | USD | 789,700,000 | ||
| Clarus DE II LP | Venture | 2014 | USD | 40,000,000 | ||
| Clarus Defined Exit I LP | Venture | 2014 | USD | 100,000,000 | ||
| Clarus Lifesciences III LP | Venture | 2014 | ||||
| Clarus Ventures III GP LP | Venture | 2014 | ||||
| Clarus Lifesciences II LP | Venture | 2008 | USD | 14.80 % | 1.80 x | |
| Clarus Lifesciences I LP | Venture | 2006 | USD | 3.90 % | 1.20 x | |
| Clarus Ventures II | Venture | USD | 697,000,000 |
Funding rounds
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
The Blackstone Group LP | Private equity firm | Led the round. |
Investment preferences
Investment activity status
Not investing
Selected investments
Displaying 1 - 25 of 38| Company | Profile | Country | Date Sort ascending | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Oxford Immunotec Ltd | Venture | ||||
|
|
Flowonix Medical | A medical device company dedicated to helping those who suffer from chronic disorders. | N/A | |||
|
|
Catabasis Pharmaceuticals Inc | Series A | ||||
|
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series D | |||
|
|
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | Series A | |||
|
|
SARcode Bioscience Inc | Series B | ||||
|
|
Aerie Pharmaceuticals Inc | Series B | ||||
|
|
TyRx Inc | N/A | ||||
|
|
Oxford Immunotec Ltd | Series D | ||||
|
|
Catabasis Pharmaceuticals Inc | Series A | ||||
|
|
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | N/A | |||
|
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | Series B Follow-on investment | |||
|
|
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series C | |||
|
|
Aerovance Inc | N/A | ||||
|
|
Lycera Corp | Series A | ||||
|
|
Heptares Therapeutics Ltd | Series A | ||||
|
|
Virdante Pharmaceuticals Inc | A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders. | Series A | |||
|
|
Biolex Therapeutics Inc | Series D | ||||
|
|
Link Medicine Inc | Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases | Series C | |||
|
|
Achillion Pharmaceuticals Inc | Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. | N/A | |||
|
|
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment | |||
|
|
Avanir Pharmaceuticals Inc | A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. | N/A | |||
|
|
TyRx Inc | N/A | ||||
|
|
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | N/A Initial investment | |||
|
|
Oxford Immunotec Ltd | Series C led the round |